EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FHL2 in arterial medial calcification in chronic kidney disease

Yuan-Ru Liao, Yu-Cheng Tsai, Tsung-Han Hsieh, Ming-Tsun Tsai iD, Feng-Yen Lin, Shing-Jong Lin, Chih-Ching Lin, Hou-Yu Chiang, Pao-Hsien Chu iD, Szu-Yuan Li iD

Nephrology Dialysis Transplantation · 2024

DOI: 10.1093/ndt/gfae091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Yuan-Ru Liao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: LIM-Homeodomain Proteins, Renal Insufficiency, Chronic, Muscle Proteins, Core Binding Factor Alpha 1 Subunit. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Chang Gung Memorial Hospital, Y.L. Lin Hung Tai Education Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Arterial medial calcification (AMC) is a common complication in individuals with chronic kidney disease (CKD), which can lead to cardiovascular morbidity and mortality. The progression of AMC is controlled by a key transcription factor called runt-related transcription factor 2 (RUNX2), which induces vascular smooth muscle cells (VSMCs) transdifferentiation into an osteogenic phenotype. However, RUNX2 has not been targeted for therapy due to its essential role in bone development. The objective of our study was to discover a RUNX2 coactivator that is highly expressed in arterial VSMCs as a potential therapy for AMC.

Methods

We employed transcriptomic analysis of human data and an animal reporter system to pinpoint four and a half LIM domains 2 (FHL2) as a potential target. Subsequently, we investigated the mRNA and protein expression patterns of FHL2 in the aortas of both human and animal subjects with CKD. To examine the role of FHL2 in the RUNX2 transcription machinery, we conducted coimmunoprecipitation and chromatin immunoprecipitation experiments. Next, we manipulated FHL2 expression in cultured VSMCs to examine its impact on high phosphate-induced transdifferentiation. Finally, we employed FHL2-null mice to confirm the role of FHL2 in the development of AMC in vivo.

Results

Among all the potential RUNX2 cofactors, FHL2 displays selective expression within the cardiovascular system. In the context of CKD subjects, FHL2 undergoes upregulation and translocation from the cytosol to the nucleus of arterial VSMCs. Once in the nucleus, FHL2 interacts structurally and functionally with RUNX2, acting as a coactivator of RUNX2. Notably, the inhibition of FHL2 expression averts transdifferentiation of VSMCs into an osteogenic phenotype and mitigates aortic calcification in uremic animals, without causing any detrimental effects on the skeletal system.

Conclusion

These observations provide evidence that FHL2 is a promising target for treating arterial calcification in patients with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LIM-Homeodomain ProteinsRenal Insufficiency, ChronicMuscle ProteinsCore Binding Factor Alpha 1 SubunitTranscription FactorsMuscle, Smooth, VascularVascular CalcificationAnimalsHumansMiceCells, CulturedMaleCell TransdifferentiationMice, Inbred C57BLMyocytes, Smooth MuscleMice, Knockout

Stichwörter der Autor:innen

FHL2RUNX2kidney diseasevascular calcificationvascular smooth muscle cell

Substanzen

LIM-Homeodomain ProteinsMuscle ProteinsCore Binding Factor Alpha 1 SubunitFHL2 protein, humanTranscription FactorsFhl2 protein, mouseRUNX2 protein, human

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Joint Biobank, Office of Human Research, Taipei Medical University, Taipei, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.

ORCID-Profile: Ming-Tsun Tsai, Pao-Hsien Chu, Szu-Yuan Li

Förderung

  • Ministry of Science and Technology
  • Chang Gung Memorial Hospital
  • Y.L. Lin Hung Tai Education Foundation

Zitieren

APA

Liao, Y. R., Tsai, Y. C., Hsieh, T. H., Tsai, M. T., Lin, F. Y., Lin, S. J., Lin, C. C., Chiang, H. Y., Chu, P. H., & Li, S. Y. (2024). FHL2 in arterial medial calcification in chronic kidney disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae091

Vancouver

Liao YR, Tsai YC, Hsieh TH, Tsai MT, Lin FY, Lin SJ, et al. FHL2 in arterial medial calcification in chronic kidney disease. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfae091

BibTeX
@article{Liao2024,
  author = {Liao, Yuan-Ru and Tsai, Yu-Cheng and Hsieh, Tsung-Han and Tsai, Ming-Tsun and Lin, Feng-Yen and Lin, Shing-Jong and Lin, Chih-Ching and Chiang, Hou-Yu and Chu, Pao-Hsien and Li, Szu-Yuan},
  title = {FHL2 in arterial medial calcification in chronic kidney disease},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  doi = {10.1093/ndt/gfae091}
}
Kostenlos starten →